Translational Oncology for Drug Development
PDOX xenograft models are a superior offering for simulating oncology clinical trials.
PDOX models are proven to be more clinically relevant than PDX.
We provide the world’s only orthotopic models utilizing Surgical Orthotopic Implantation. Only PDOX models metastasize similar to clinical cancer. In PDOX models, the primary tumor develops in the organ corresponding to its origin and metastasizes to mimic the complexity of tumor behavior in patients. PDOX models are therefore the most clinically relevant for drug discovery and evaluation.
PDOX’s multiple simultaneous implants increases the accuracy of therapy and reduces the time to treat aggressive tumors. This provides a significant, sustainable competitive advantage over existing mouse models.
PDOX provides expanded opportunities over traditional PDX and CDX models.
- Allows the evaluation of anti-metastatic effects of agents, given the propensity of orthotopically implanted tumors to metastasize.
- Less susceptible to false positives and false negatives than subcutaneous implanted tumors.
- Delivers the ability to survey a wide variety of tumor types to confirm Responder ID hypotheses.
- Shown to maintain genetic fidelity from patient material through several passages.
With our PDOXs, you can perform next-generation studies, including:
- Drug screening for efficacy against PDOXs of multiple cancer types
- Drug sensitivity
Typical PDOX study endpoints
- Tumor size reduction and regression (data are available in real-time with imaging, with
resolution of a single cancer cell in vivo)
- Tumor growth delay or regression
- Decrease or elimination of metastasis (data are available with real-time imaging)
- Drug effects on host as well as tumors
- Increase in overall survival and disease-free survival
- Changes in biomarkers
- Tumor histology
- Tumor immunohistochemistry.